Literature DB >> 11106080

Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas.

B E King1, C Chen, J Locker, J Kant, K Okuyama, B Falini, S H Swerdlow.   

Abstract

Diffuse large B-cell lymphomas (DLBCL) are a biologically and clinically heterogeneous entity. Although some DLBCL represent transformation of follicular lymphomas (FL), the proportion that is of follicular center cell (FCC) origin remains uncertain. Immunophenotypic and genotypic markers used to suggest a FCC origin for a lymphoma (bcl-6 and CD10 expression, lack of CD138 expression, bcl-2 rearrangements [R]) or to subdivide DLBCL (bcl-2 expression, bcl-6 R) were therefore investigated in 22 FL and 44 DLBCL using paraffin section immunostains and Southern blot/polymerase chain reaction analysis. All FL tested were bcl-6+ (19) and CD138- (22) with 16/19 also bcl-2 and CD10+ (classic phenotype), one bcl2+, CD10- (grade III) and two bcl2-, CD10+ (grade II or III). Bcl-2R was identified in 4/5 FL-GrI, 3/6 FL-GrII, and 1/3 FL-GrIII. Bcl-6R was found in 0/5, 2/4, and 0/3 FL, respectively. All but 3/41 DLBCL were bcl-6+ with 17/37 also bcl-2+ and CD10+. Three of these cases were also CD138+. Twelve bcl-6+ cases were bcl-2+, CD10-, six bcl-2-, CD10+, and two bcl-2-, CD10-. The three bcl-6- cases were bcl-2+, CD138- and two were CD10+. Bcl-2R was identified in 5/27 DLBCL with 4/5 bcl-2+, 3/4 tested CD10+ and 4/4 bcl-6+. Bcl-6R was identified in 7/26 including three with a classic FL phenotype. The vast majority of DLBCL in this study have an immunophenotype that supports a FCC origin. Although the proportion of DLBCL that co-expressed bcl-6, CD10 and bcl-2 was lower than for the FL, absence of bcl-2 or CD10 may be associated with higher grade FL It is also possible that bcl-6 expression is not completely specific for a FCC origin. Only a minority of cases suggested postfollicular differentiation. Only a minority of DLBCL show bcl-2R, suggesting that many have a different molecular pathogenesis than most low-grade FL. Bcl-6R did not exclude a FCC origin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106080     DOI: 10.1038/modpathol.3880226

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

Review 1.  Nodal aggressive B-cell lymphomas: a diagnostic approach.

Authors:  Sonam Prakash; Steven H Swerdlow
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

2.  High frequency of germinal centre derivation in diffuse large B cell lymphoma from Asian patients.

Authors:  A K H Shia; G-G Gan; S Jairaman; S-C Peh
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

3.  Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q.

Authors:  Ronald Boonstra; Alice Koning; Mirjam Mastik; Anke van den Berg; Sibrand Poppema
Journal:  Virchows Arch       Date:  2003-06-12       Impact factor: 4.064

4.  Distinct pattern of lymphoid neoplasms characterizations according to the WHO classification (2016) and prevalence of associated Epstein-Barr virus infection in Nigeria population.

Authors:  Ijeoma C Uzoma; Idowu A Taiwo; Massimo Granai; Gioia Di Stefano; Ester Sorrentino; Sussana Mannucci; Muheez A Durosinmi; Stefano Lazzi; Lorenzo Leoncini; Oluyemi Akinloye
Journal:  Infect Agent Cancer       Date:  2021-05-24       Impact factor: 2.965

5.  Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.

Authors:  Alexandar Tzankov; Philip Went; Stephan Dirnhofer
Journal:  Biomark Insights       Date:  2007-11-11

6.  Smad1 expression in follicular lymphoma.

Authors:  Jai Hyang Go
Journal:  J Pathol Transl Med       Date:  2015-05-15

7.  R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.

Authors:  Xiao-Hui He; Bo Li; Sheng Yang; Ning Lu; Xun Zhang; Shuang-Mei Zou; Ye-Xiong Li; Yong-Wen Song; Shan Zheng; Mei Dong; Sheng-Yu Zhou; Jian-Liang Yang; Peng Liu; Chang-Gong Zhang; Yan Qin; Feng-Yi Feng; Yuan-Kai Shi
Journal:  Chin J Cancer       Date:  2012-05-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.